IceCure Medical Secures $5.5M Private Placement, Seeks Warrant Price Cut to $3.00
ICCM•IceCure Medical raised $5.5 million in a private placement by selling 1,833,334 shares and warrants at $3.00 per unit to a healthcare-focused institutional investor. The company will use proceeds for working capital and seeks shareholder approval to cut exercise prices of 266,666 existing warrants from $16.50 to $3.00, raising dilution.
1. Private Placement Terms
IceCure Medical entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 1,833,334 ordinary shares and an equal number of Series D and Series E warrants at $3.00 per share and warrant unit, generating approximately $5.5 million in gross proceeds. The Series D warrants expire five years after issuance and the Series E warrants expire one year after issuance, both exercisable immediately at $3.00 per share.
2. Proceeds Use and Closing
The company expects to close the offering on or about June 18, 2026, subject to customary conditions. Net proceeds will be allocated to working capital and general corporate purposes to support ongoing operations and growth initiatives.
3. Warrant Amendment Proposal
IceCure has agreed, subject to shareholder approval, to amend Series B and Series C warrants issued in March 2026, reducing the exercise price for an aggregate of 266,666 warrants from $16.50 to $3.00. The amended Series B warrants will expire in June 2031 and the amended Series C warrants in June 2027, increasing potential dilution upon exercise.
